KIT and gastrointestinal stromal tumor: GIST patients with c-KIT exon 9 mutation is associated with lower response rate to imatinib than those with c-KIT exon 11 mutation and higher dose of imatinib is suggested for GIST patients harboring c-KIT exon 9 mutation [19, 22].